Other substances

Autologous conditioned serum

A blood product.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
2
 Clinical trials

General information

Autologous conditioned serum (ACS) is prepared by a treatment of the patient’s blood in which the cells within the serum produce compounds such as IL-1R antagonist (the recombinant form is termed Anakinra). The patient is then reinjected a fraction of the serum. ACS has been studied for the treatment of osteoarthritis (Evans et al., 2016).

Autologous conditioned serum on Wikipedia

Synonyms

ACS

 

Supporting references

Link Tested on Impact factor Notes Publication date
Intratracheal administration of autologus conditioned serum for COVID-19 associated respiratory distress syndrome
IL-1 Critical severity Case series Mixed substance 		Patients 2.69

Decrease in body temperature and CRP levels upon intratracheal injection. Improvement in driving pressure and oxygenation index. Radiological improvement in some patients. Sample size: 5.

 Aug/20/2020

AI-suggested references

Link Publication date
Hyperhemolysis in a patient with sickle cell disease and recent SARS-COV-2 infection, with complex auto- and allo-antibody work-up, successfully treated with tocilizumab.
Oct/25/2021
Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
Aug/14/2020
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
Mar/04/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04691609 Assiut University Registry for ACS Patients During COVID-19 Pandemic Recruiting Mar/01/2020 Sep/01/2023
  • Alternative id - ACS in COVID-19 era
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Samah ObiedAllah Fouad, Assiut, Resident, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Cross-Sectional
  • Enrollment - 2500
  • Age - Child, Adult, Older Adult
  • Outcome measures - Main Number, distribution and oucome of all ACS patients coming to Assiut heart hospital|To register pathological events occurring to all acute coronary syndrome patients coming to Assiut university heart hospital through one year during COVID- 19 pandemic
NCT04412655 Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry Active, not recruiting May/05/2020 Jun/02/2020
  • Alternative id - 115/20
  • Interventions - Device: Percutaneous Coronary Revascularization for STEMI
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Giuseppe De Luca, Novara, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 6609
  • Age - Child, Adult, Older Adult
  • Outcome measures - Number of patients undergoing primary angioplasty|Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;|Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission|In-hospital mortality
Export (.csv)